Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Justin Manley

Vascular Surgery Flowood, MS Medical Doctor

NPI 1871780544 CMS profile 587374

4436 Mangum Dr, Flowood, MS 39232

Open in the dashboard

General payments

$30,061

134 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Justin Manley of Flowood, MS is reported in the CMS Open Payments database as having received $30,061 across 134 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,167 23
2024 General $11,418 25
2023 General $2,132 29
2022 General $1,871 30
2021 General $1,932 23
2020 General $541 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Justin Manley
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Justin Manley were reported at $12,167. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Justin Manley Vascular Surgery median Middle half National median
2019 $0 $796 $226–$2,363 $163
2020 $541 $348 $118–$1,110 $114
2021 $1,932 $471 $158–$1,421 $132
2022 $1,871 $725 $222–$2,183 $149
2023 $2,132 $836 $257–$2,440 $160
2024 $11,418 $909 $252–$2,619 $164
2025 $12,167 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AngioDynamics, Inc. $22,397 15 payments
  2. Medtronic, Inc. $3,091 44 payments
  3. W. L. Gore & Associates, Inc. $3,031 48 payments
  4. Kerecis Limited $383 2 payments
  5. Inari Medical, Inc. $277 3 payments
  6. Stryker Corporation $148 2 payments
  7. Terumo Medical Corporation $142 2 payments
  8. Boston Scientific Corporation $136 7 payments
  9. Shockwave Medical, Inc $115 1 payment
  10. LeMaitre Vascular, Inc. $115 1 payment
  11. Other $226 9 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Long term medical supply or device loan $21,208 2 payments
  2. Food and Beverage $6,938 118 payments
  3. Travel and Lodging $1,695 12 payments
  4. Education $220 2 payments
Products named General payments · program years 2020–2025
  1. Auryon Laser System 100-120 Vac Cv $11,208 1 payment
  2. Auryon Laser System 100-120 Vac Et $10,245 2 payments
  3. TurboHawk $1,598 24 payments
  4. AURYON LASER SYSTEM 100-120 VAC Pad $944 12 payments
  5. EXCLUDER Conformable AAA Endoprosthesis with Active Control $734 11 payments
  6. HawkOne $512 5 payments
  7. GORE TAG Thoracic Endoprosthesis $501 7 payments
  8. GORE VIABAHN Endoprosthesis $404 6 payments
  9. GORE EXCLUDER AAA Endoprosthesis $375 6 payments
  10. CT THROMBECTOMY SYSTEM KIT $277 3 payments
  11. Other $3,893 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

43

Median for Vascular Surgery: 122

Drug cost

$17,008

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 24 $16,823
Clopidogrel Clopidogrel Bisulfate Brand 19 $185

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$234,595

Medicare's payments for the services billed

Medicare patients

341

Average age 75

Services billed

1,025

164 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 55%
Ischemic heart disease 43%
Chronic kidney disease 42%
Heart failure 33%
Depression 32%
Atrial fibrillation 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

134 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record